Ads
related to: psa testing nhs leaflet sample template download free powerpointaippt.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene.PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.
Used in conjunction with a PSA test, the PSE test boosts accuracy from 55% to 94% offering a more effective and precise method for detecting and diagnosing prostate cancer. [45] The 4Kscore combines total, free, and intact PSA with human kallikrein 2. [46] It is used to try to determine the risk of a Gleason score greater than 6. [46]
Date/Time Thumbnail Dimensions User Comment; current: 13:17, 15 September 2014: 772 × 1,214, 4 pages (425 KB): Djr13: remake PDF to crop blank areas: 18:02, 1 December 2012
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of the prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
PAP immunohistochemical staining is often used with PSA (staining), by pathologists, to help distinguish poorly differentiated carcinomas.For example, poorly differentiated prostate adenocarcinoma (prostate cancer) and urothelial carcinoma (bladder cancer) may appear similar under the microscope, but PAP and PSA staining can help differentiate them; [7] prostate adenocarcinoma often stains ...
The SPC is not intended to give general advice about treatment of a condition but does state how the product is to be used for a specific treatment. It forms the basis of information for health professionals to know how to use the specific product safely and effectively. The package leaflet supplied with the product is aimed at end-users. [3]